Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

152.65 +1.52 (+1.01%)
Official Closing Price Updated: 7:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,696,849
Open 151.48
Bid (Size) 152.30 (33)
Ask (Size) 152.90 (30)
Prev. Close 151.13
Today's Range 150.83 - 152.76
52wk Range 150.11 - 186.69
Shares Outstanding 2,628,679,824
Dividend Yield 2.65%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Better Buy: AbbVie vs. Johnson & Johnson
These pharma giants beat the bear market last year. 
Via The Motley Fool
Study Shows 186 Banks Are On The Brink Of Failure
The Fed has done it again: raised their interest rates for the 9th time on March 22, 2023, by 25 basis points. This brings the fed fund rate to 4.75%-5%. However, this move sent mixed signals. 
Via Talk Markets

Performance

YTD
-14.33%
-14.33%
1 Month
-3.25%
-3.25%
3 Month
-13.99%
-13.99%
6 Month
-8.44%
-8.44%
1 Year
-12.89%
-12.89%

More News

Read More
New Regional Director for EMEA to Drive Next Stage of Growth Across the Region for Jeron Nurse Call Systems
Via PRLog
Topics Economy
Exposures Supply Chain
Looking At Johnson & Johnson's Recent Unusual Options Activity
Via Benzinga
Ready to Buy the Dip? Johnson & Johnson Stock Is a Smart Buy
Via The Motley Fool
Binance Suspends Trading, European Bank Trouble, Twitter To Remove Legacy Verified Checkmarks: Today's Top Stories
Via Benzinga
Johnson & Johnson Loses Key Tuberculosis Drug Patent In India, Makes Way For Domestic Generic Players
Via Benzinga
Have $1,000? 2 Smart Stocks to Buy This Month
Via The Motley Fool
3 Safe Dow Dividend Stocks to Buy Now
Via The Motley Fool
Think the Bear Market Is Over? Here's How to Invest $5,000
Via The Motley Fool
Looking Into Johnson & Johnson's Recent Short Interest
Via Benzinga
Johnson & Johnson Unusual Options Activity
Via Benzinga
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
Via TheNewswire.com
Exposures Product Safety
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
Via News Direct
Exposures Product Safety
2 Stocks That Should Be Better Buys After Their Spinoffs This Year
Via The Motley Fool
Where Did COVID-19 Really Originate? Biden Signs Bill To Declassify Origins Information
Via Benzinga
3 Dow Stocks Near 52-Week Lows That Look Like Bargains Now
Via The Motley Fool
Top 8 Stocks To Profit From Rising Interest Rates
Via Talk Markets
3 Retirement Investing Moves to Help Get You Back on Track
Via The Motley Fool
5 Stocks You Can Confidently Invest $500 in Right Now
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Medicare Negotiation Hammers Biotech Stocks Regeneron, Halozyme
Via Investor's Business Daily
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
From Johnson & Johnson
Via Business Wire
Johnson & Johnson's Experimental Dengue Pill Shows Efficacy In Animal Studies
Via Benzinga
7 Blue-Chip Stocks to Buy and Hold for Decades
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.